Parfitt AM, Villanueva AR, Foldes J, Rao DS. Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res. 1995;10:466–73.
Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202–9.
Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, et al. The role of Dickkopf‑1 in bone development, homeostasis, and disease. Blood. 2009;113:517–25.
Ke HZ, Richards WG, Li X, et al. Sclerostin and dickkopf 1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33:747–83.
Van Buchem FS, Hadders HN, Ubbens R. An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol. 1955;44:109–20.
Truswell AS. Osteopetrosis with syndactyly, a morphologic variant of Albers-Schönberg disease. J Bone Joint Surg. 1958;40:208–18.
Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537–43.
Van Lierop AH, Hamdy NAT, van Egmond ME, et al. Van Buchem Disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res. 2013;28:848–54.
Compton MS, Lee FY. A review of Osteocyte function and the emerging importance of Sclerostin. J Bone Joint Surg. 2014;96:1659–68.
Semenov M, Tamai K, He X. SOST is a ligand for LRP5/6 and a Wnt signaling inhibitor. J Biol Chem. 2005;260:770–5.
Drake MT, Srinivsan B, Mödder UI, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010;95:5056–62.
Farr JN, Roforth MM, Fujita K, et al. Effects of age and estrogen on skeletal gene expression in humans as assessed by RNA sequencing. PLoS ONE. 2015;10:e138347.
Rauner M, Sipos W, Pietschmann P. Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation. Age. 2008;30:273–82.
Modder UI, Clowed JA, Hoey K, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011;26:27–43.
Amrein K, Amrein S, Drexler C, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012;97:48–54.
Ardawi MS, Rouzi AA, Al-Sibiani SA, et al. High sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research study. J Bone Miner Res. 2012;27:2592–602.
Moriwaki K, Matsumoto H, Tanishima S, et al. Association of serum bone- and muscle-derived factors with age, sex, body composition, and physical function in community-dwelling middle-aged and elderly adults: a cross-sectional study. BMC Musculoskelet Disord. 2019;20:276. https://doi.org/10.1186/s12891-019-2650-9.
Kalem MN, Kalem Z, Akgum N, et al. The relationship between postmenopausal women’s sclerostin levels andtheir bone density, age, body mass index, hormonal status, and smoking and consumption of coffee and dairy products. Arch Gynecol Obstet. 2017;295:785–93.
Dawson-Hughes B, Harris SS, Ceglia L, et al. Serum sclerostin levels vary with season. J Clin Endocrinol Metab. 2014;99:E149–E52.
Robling AG, Niziolek PJ, Baldidge LA, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008;283:5866–75.
Lin C, Jiang X, Dai Z, et al. Sclerostin mediated bone response to mechanical unloading through antagonizing Wnt/ß-catenin signaling. J Bone Miner Res. 2009;24:1651–61.
Hinton PS, Nigh P, Thyfault J. Serum sclerostin deceases following 12 months of resistance or jump-training in men with low bone mass. Bone. 2017;96:85–90.
Kerschan-Schindl K, Thalmann M, Weiss E, et al. Changes in serum levels of myokines and Wnt-antagonists after an ultramarathon race. PLoS ONE. 2015;10:e132478.
Kouvelioti R, Kurgan N, Falk B, et al. Cytokine and sclerostin response to high-intensity interval running versus cycling. Med Sci Sports. 2019; https://doi.org/10.1249/MSS.0000000000002076.
Gaudio A, Pennisi P, Bratengeier C, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010;95:2248–53.
Arasu A, Cawthon PM, Lui LY, et al. Serum sclerostin and risk of hip fracture in older Causasian women. J Clin Endocrinol Metab. 2012;97:2027–32.
Garnero P, Sornay-Rendu E, Munoz F, et al. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013;24:489–94.
Szulc P, Bertholon C, Borel O, et al. Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res. 2013;28:855–64.
Amrein K, Dobnig H, Wagner D, et al. Sclerostin in institutionalized elderly women: associations with quantitative bone ultrasound, bone turnover, fractures, and mortality. J Am Geriatr Soc. 2014;62:1023–9.
Ueland T, Stilgren L, Bollerslev J. Bone matrix levels of dickkopf and sclerostin are positively correlated with bone mass and strength in postmenopausal osteoporosis. Int J Mol Sci. 2019;20:2896. https://doi.org/10.3390/ijms20122896.
Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860–9.
Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578–88.
Li X, Warmington KS, Asuncion FJ, et al. Progressive increases in bone mass and bone strength in an ovarectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology. 2014;155:4785–97.
Stoliuna M, Dwyer D, Niu QT, et al. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone. 2014;67:305–13.
Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25:2647–56.
Li X, Ominsky MS, Villsenor KS, et al. Sclerostin antibody reverses bone loss by increasing bone formation and decreasing bone resorption in rat model of male osteoporosis. Endocrinology. 2018;59:260–71.
Tian XY, Setterberg RB, Li X, et al. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone. 2010;47:529–33.
Li X, Ominsky MS, Warmington KS. Increased bone formation and bone mass induced by of sclerostin antibody is not affected by retreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011;152:3312–22.
Ominsky MS, Boyce RW, Li X, et al. Effects of sclerostin antibodies in animal models of osteoporosis. Bone. 2017;96:63–75.
Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res. 2009;24:1662–71.
Ominsky MS, Vlasserros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25:948–59.
Ominsky MS, Boyd SK, Varela A, et al. Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2016;32:788–801.
Li C, Ominsky MS, Tan HL, et al. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone. 2011;49:1178–85.
Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone heling and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011;26:1012–21.
Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19–26.
Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2014;54:168–78.
Graeff C, Campbell GM, Pena J, et al. Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone. 2015;81:364–9.
McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Eng J Med. 2014;370:412–20.
Genant HK, Engelke K, Bolognese MA, et al. Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32:181–7.
Keaveny TM, Crittenden DB, Bolognese MA, et al. Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32:1956–62.
McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab of placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33:1397–406.
Ishibashi H, Crittenden DB, Miyauchi A, et al. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis. Bone. 2017;103:209–15.
Langdahl B, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390:1585–93.
Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Eng J Med. 2016;375:1532–43.
Cosman F, Crittenden DB, Ferrari S, et al. Romosozumb FRAME Study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res. 2018;33:1407–16.
Cosman F, Crittenden DB, Ferrari S, et al. FRAME Study: The foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res. 2018;33:1219–26.
Saag KG, Petersen J, Brandi MI, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Eng J Med. 2017;377:1417–27.
Lewiecki EM, Blicharski T, Goemaere S, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with oteoporosis. J Clin Endocrinol Metab. 2018;103:3183–93.
Krishnamarthy N, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: update on effects and inhibitors. Cancer Treat Rev. 2018;62:50–60.
Chouinard L, Felx M, Mellal N, et al. Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of evidence and findings in a rat lifetime pharmacology study. Reg Toxicol Pharmakol. 2016;81:212–22.
McClung MR. Romosozumab for the treatment of osteoporosis. Review article. Osteoporos Sarcopenia. 2018;4:11–5.
McColm J, Hu L, Womack T, et al. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014;29:935–43.
Recker RR, Benson CT, Matsumoto T, et al. A randomized, double blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30:216–24.
Recknor CP, Recker R, Benson CT, et al. The effect of discontinuing treatment with blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30:1717–25.
Seefried L, Baumann J, Hemsley S, Hofmann C, Kunstmann E, Kiese B, et al. Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J Clin Invest. 2017;127:2148–58.
Glorieux FH, Devogelaer JP, Durigova M, Goemaere S, Hemsley S, Jakob F, et al. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J Bone Miner Res. 2017;32:1496–504.
EVENITY™ (romosozumab-aqqg) U.S. Prescribing Information https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/evenity/evenity_pi_hcp_english.ashx. Accessed 28.11.2019
https://www.ema.europa.eu/en/medicines/human/summaries-opinion/evenity. Accessed 28.11.2019